Scholarlink

Background <p>In recent decades, infections caused by <i>C.parapsilosis</i> have been increasingly reported, particularly strains of <i>C.parapsilosis</i> that are non-susceptible to fluconazole.</p> Aims <p>We aimed to evaluate candidemia episodes caused by <i>C. parapsilosis</i> (CP) and compare them with candidemia episodes caused by non-<i>parapsilosis Candida</i> spp. (non-CP). Furthermore, we examined the risk factors and outcomes of <i>C.parapsilosis</i> candidemia based on fluconazole susceptibility [fluconazole susceptible: FS, fluconazole non-susceptible: FNS] from January 2008 to December 2022 at Ege University.</p> Results <p>Of the 423 episodes of candidemia, <i>C.parapsilosis</i> was the most common, identified in 195 cases (46.1%). The rate of fluconazole non-susceptibility was 48.3%. Multivariate analysis indicated that fluconazole exposure and the presence of tracheostomy were significant risk factors for <i>C. parapsilosis</i> candidemia (32.3% vs. 18.9%; <i>p</i> =0.006 ; OR = 1.917; 95% CI:1.210–3.037) and (12.8% vs. 5.7%; <i>p</i> = 0.047; OR = 2.125 (1.010-4.469), respectively. The attributable mortality(AM) rate and crude mortality(CM) rates were slightly higher in the non-CP group than in the CP group without a significant difference (<i>p</i> &gt; 0.005). Fluconazole non-susceptibility was significantly associated with antifungal exposure (<i>p</i> = 0.047; OR = 2.119; 95% CI = 1.012–4.437) and did not alter outcomes, including AM and CM (<i>p</i> &gt; 0.05).</p> Conclusions <p>This study identified significant associations between fluconazole exposure and tracheostomy with subsequent <i>C.parapsilosis</i> candidemia. Notably, antifungal exposure was the only clinical risk factor identified for the development of fluconazole resistance. The increasing incidence of fluconazole resistance should prompt clinicians to consider using an echinocandin in empirical therapy.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Analysis of the risk factors associated with bloodstream infections caused by Candida parapsilosis in pediatric patients and the determinants of fluconazole non-susceptibility: a retrospective 15-year cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • Zumrut Sahbudak Bal,
  • Sema Yildirim Arslan,
  • Gizem Guner Ozenen,
  • Gülizar Turan,
  • Kübra Cebeci,
  • Ulgen Celtik,
  • Gulhadiye Avcu,
  • Nihal Karadas,
  • Gulcihan Ozek,
  • Miray Karakoyun,
  • Dilek Yesim Metin,
  • Suleyha Hilmioglu Polat

摘要

Background

In recent decades, infections caused by C.parapsilosis have been increasingly reported, particularly strains of C.parapsilosis that are non-susceptible to fluconazole.

Aims

We aimed to evaluate candidemia episodes caused by C. parapsilosis (CP) and compare them with candidemia episodes caused by non-parapsilosis Candida spp. (non-CP). Furthermore, we examined the risk factors and outcomes of C.parapsilosis candidemia based on fluconazole susceptibility [fluconazole susceptible: FS, fluconazole non-susceptible: FNS] from January 2008 to December 2022 at Ege University.

Results

Of the 423 episodes of candidemia, C.parapsilosis was the most common, identified in 195 cases (46.1%). The rate of fluconazole non-susceptibility was 48.3%. Multivariate analysis indicated that fluconazole exposure and the presence of tracheostomy were significant risk factors for C. parapsilosis candidemia (32.3% vs. 18.9%; p =0.006 ; OR = 1.917; 95% CI:1.210–3.037) and (12.8% vs. 5.7%; p = 0.047; OR = 2.125 (1.010-4.469), respectively. The attributable mortality(AM) rate and crude mortality(CM) rates were slightly higher in the non-CP group than in the CP group without a significant difference (p > 0.005). Fluconazole non-susceptibility was significantly associated with antifungal exposure (p = 0.047; OR = 2.119; 95% CI = 1.012–4.437) and did not alter outcomes, including AM and CM (p > 0.05).

Conclusions

This study identified significant associations between fluconazole exposure and tracheostomy with subsequent C.parapsilosis candidemia. Notably, antifungal exposure was the only clinical risk factor identified for the development of fluconazole resistance. The increasing incidence of fluconazole resistance should prompt clinicians to consider using an echinocandin in empirical therapy.

Clinical trial number

Not applicable.